Kokeile maksutta

Hankinnat

HankinnatPäättyvät sopimuksetVoittajat

Markkinat

ToimialatHankinta­yksikötToimittajat

Tarjoustilanne

HinnatTietoa datasta ja meistä
Kokeile Pro-tasoa maksutta 14 päivääKirjaudu
Suljettu (englanniksi)Hankinta · julkaistu 15.4.2024

Various pharmaceutical products / 2024-2025

Terveyden ja hyvinvoinnin laitos, Helsinki. Hankitaan terveydenhuollon laitteet, lääkkeet ja hygieniatuotteet.

Tarjousten määräaika 3.5.2024Arvo ei ilmoitettuSopimuskausi 1,1 vMenettely avoin menettelyHankinta-asiakirjoihin ↗

Hankintapäätös on tehty. Katsokaa, kuka voitti (päätös 29.10.2024)

Tilanne teille

Kolme asiaa, jotka kannattaa punnita ennen kuin käytätte aikaa tarjoukseen

  • AikaTarjousaika on päättynytMääräpäivä oli 3.5.2024
  • KilpailuVähäinen kilpailu≈ 8,4 tarjousta keskimäärin alalla terveydenhuollon laitteet, lääkkeet ja hygieniatuotteet, CPV 33600 koko Suomessa
  • Kuka yleensä voittaaEi selvää suosikkia3 eri voittajaa 3 viimeisimmässä sopimuksessa

Yritysprofiilin avulla näytämme myös, kuinka hyvin hankinta sopii teille. Luo tili – kokeile maksutta 14 päivää

Tarjoustaulu on luettelonne hankinnoista, joita harkitsette tai joiden parissa työskentelette, vaiheittain ensimmäisestä vilkaisusta jätettyyn tarjoukseen.

Lisää tarjoustauluun Tilaa hakuvahti vastaavista hankinnoista Lähetä kollegalle

Kilpailutilanne

Kuka on voittanut hankintayksikön sopimukset ja montako tarjousta yleensä jätetään

Hankintayksikön viimeisimmät vastaavat sopimukset

PäätösVoittaja ja sopimusTarjouksiaArvo
30.3.2026Roche Diagnostics OyAnalyysilaitteiston (Sysmex verenkuva-analysaattori XN-1000) reagenssit ja huoltosopimus120 000 €–120 000 €
26.2.2026Voittajaa ei julkaistuAzithromycin oral suspension 40 mg/ml - SUSPENDED––
22.12.2025Voittajaa ei julkaistuAzithromycin oral suspension 40 mg/ml - SUSPENDED––
16.12.2025BioNordika OyWGS kirjastokitit269 000 €–269 000 €
18.11.2025MIP Pharma Holding GmbHClindamycin 150 mg/ml (4ml per vial/ampoule)618 000 €–618 000 €
17.11.2025Voittajaa ei julkaistuNextera XT Library Preparation Kit––

Näin monta tarjousta yleensä jätetään

Vähäinen kilpailu. Vastaavat hankinnat saavat keskimäärin 8,4 tarjousta.

Keskiarvo koskee alaa terveydenhuollon laitteet, lääkkeet ja hygieniatuotteet, CPV 33600 koko Suomessa viimeisten kolmen vuoden ajalta.

Tarjousten määrä hankintapäätöstä kohden
Tarjouksia keskimäärin
8,4
Sai vain yhden tarjouksen
72 %
Sopimusarvon mediaani
940 000 €
Pk-yritysten voittamia
50 %

Todennäköiset kilpailijat

Novartis Finland Oy on voittanut eniten sopimuksia alalla terveydenhuollon laitteet, lääkkeet ja hygieniatuotteet, CPV 33600 koko Suomessa: 9 viimeisten kolmen vuoden aikana, arvoltaan 23 milj. €.

+ 7 muuta Pro-tasolla, voittojen määrä ja sopimusarvo mukanaKokeile Pro-tasoa maksutta
Kilpailu juuri alueella Uusimaa verrattuna koko SuomeenKokeile Pro-tasoa maksutta

LÄHDETED36 hankintapäätöstä, joissa on ilmoitettu tarjousten määrä, kolme vuottaArviokeskiarvot ja osuudet laskenut Tarjoustilanne

Mitä hankitaan

Ilmoituksen teksti sellaisenaan

Finnish Institute for Health and Welfare, later referred to as THL or Customer, request your tender for Various pharmaceutical products to the rescEU project. The Scope of procurement is described in more detail in Annex 1. The procurement is divided in fifteen (15) lots. Each product constitutes a separate lot. Tender may be submitted for one or several lots. - LOT 1: Morphine 10-20 mg/ml (1-5 ml per vial/ampoule, i.m., ATC N02AA01) - LOT 2: Ondansetron 2 mg/ml (2-4 ml per vial/ampoule, i.m. and i.v., ATC A04AA01) - LOT 3: Ondansetron 4-8 mg per tablet/capsule, oral (ATC A04AA01) - LOT 4: Hydrocortisone 250 mg / 2 ml (2 ml per vial/ampoule i.v., ATC H02AB09) - LOT 5: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml per vial/ampoule, i.v. and i.m., ATC C01CA24) - LOT 6: Diazepam 10 mg / 2 ml (2 ml per vial/ampoule, i.m. and i.v., ATC N05BA01) - LOT 7: Midazolam 1-5 mg/ml (3-10 ml per vial/ampoule, i.v., ATC N05CD08) - LOT 8: Salbutamol 200 µg/dose (inhaler, 60 or 200 doses, ATC R03AC02) - LOT 9: Budesonide 0,5 mg/ml (2 ml nebuliser suspension per respule, ATC R03BA02) - LOT 10: Ciprofloxacin 2 mg/ml (100-200 ml per vial/ampoule, i.v., ATC J01MA02) - LOT 11: Streptomycin 1 g per vial/ampoule, i.m. (ATC J01GA01) - LOT 12: Meropenem 500-1000 mg per vial/ampoule, i.v. (ATC J01DH02) - LOT 13: Clindamycin 600 mg / 4 ml (4 ml per vial/ampoule, i.m. and i.v., ATC J01FF01) - LOT 14: Ciprofloxacin 250-500 mg per tablet/capsule, oral (ATC J01MA02) - LOT 15: Ethanol 95-96 % (5-20 ml per vial/ampoule, i.v., ATC V03AB16) The minimum requirements for the products is described in Annex 1.1. The Contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the contract has been signed by Contracting parties and expires when all contractual duties of the Contract have been performed. Estimated quantity for the products is described in Annex 6 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Supplier is not obliged to deliver the products under the Option. Please note that all times given in the Call for tenders refer to local time in Finland. Call for tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Contract Annex 3 Security annex Annex 4 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 5 Confidentiality commitment Annex 6 Estimated quantity (restricted, TL IV) Please note that the numbering of the annexes differs between the Contract and the Call for tenders.
Näytä koko kuvaus
Hankinta on jaettu 15 osaan. Tarjouksen voi jättää enintään 15 osaan.
  1. LOT 1: Morphine 10-20 mg/ml (1-5 ml per vial/ampoule, i.m., ATC N02AA01)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Morphine 10-20 mg/ml (1-5 ml per vial/ampoule, i.m., ATC N02AA01) - Intramuscular administration - Active pharmaceutical ingredient: Morphine - Strength: 10-20 mg/ml - Pharmaceutical form: 1-5 ml per vial/ampoule The minimum requirements of the Article is described in more detail in A…

  2. LOT 2: Ondansetron 2 mg/ml (2-4 ml per vial/ampoule, i.m. and i.v., ATC A04AA01)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Ondansetron 2 mg/ml (2-4 ml per vial/ampoule, i.m. and i.v., ATC A04AA01) - Intramuscular administration and intravenous administration - Active pharmaceutical ingredient: Ondansetron - Strength: 2 mg/ml - Pharmaceutical form: 2-4 ml per vial/ampoule The minimum requirements of the Ar…

  3. LOT 3: Ondansetron 4-8 mg per tablet/capsule, oral (ATC A04AA01)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Ondansetron 4-8 mg per tablet/capsule, oral (ATC A04AA01) - Oral solid dosage form - Active pharmaceutical ingredient: Ondansetron - Strength: 4-8 mg per tablet/capsule - Pharmaceutical form: tablet/capsule The minimum requirements of the Article is described in more detail in Annex 1…

  4. LOT 4: Hydrocortisone 250 mg / 2 ml (2 ml per vial/ampoule i.v., ATC H02AB09)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Hydrocortisone 250 mg / 2 ml (2 ml per vial/ampoule i.v., ATC H02AB09) - Powder for solution,, intravenous administration - Active pharmaceutical ingredient: Hydrocortisone - Strength: 250 mg / 2 ml - Pharmaceutical form: 2 ml per vial/ampoule The minimum requirements of the Article i…

  5. LOT 5: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml per vial/ampoule, i.v. and i.m., ATC C01CA24)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml per vial/ampoule, i.v. and i.m., ATC C01CA24) - Intravenous administration and intramuscular administration - Active pharmaceutical ingredient: Epinephrine (Adrenaline) - Strength: 1 mg/ml - Pharmaceutical form: 1-5 ml per vial/ampoule, the lab…

  6. LOT 6: Diazepam 10 mg / 2 ml (2 ml per vial/ampoule, i.m. and i.v., ATC N05BA01)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Diazepam 10 mg / 2 ml (2 ml per vial/ampoule, i.m. and i.v., ATC N05BA01) - Intramuscular administration and intravenous administration - Active pharmaceutical ingredient: Diazepam - Strength: 10 mg / 2 ml - Pharmaceutical form: 2 ml per vial/ampoule The minimum requirements of the Ar…

  7. LOT 7: Midazolam 1-5 mg/ml (3-10 ml per vial/ampoule, i.v., ATC N05CD08)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Midazolam 1-5 mg/ml (3-10 ml per vial/ampoule, i.v., ATC N05CD08) - Intravenous administration - Active pharmaceutical ingredient: Midazolam - Strength: 1-5 mg/ml - Pharmaceutical form: 3-10 ml per vial/ampoule The minimum requirements of the Article is described in more detail in Ann…

  8. LOT 8: Salbutamol 200 µg/dose (inhaler, 60 or 200 doses, ATC R03AC02)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Salbutamol 200 µg/dose (inhaler, 60 or 200 doses, ATC R03AC02) - Inhalation - Active pharmaceutical ingredient: Salbutamol - Strength: 200 µg/dose - Pharmaceutical form: 60 or 200 doses per inhaler The minimum requirements of the Article is described in more detail in Annex 1.1. The d…

  9. LOT 9: Budesonide 0,5 mg/ml (2 ml nebuliser suspension per respule, ATC R03BA02)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Budesonide 0,5 mg/ml (2 ml nebuliser suspension per respule, ATC R03BA02) - Inhalation - Active pharmaceutical ingredient: Budesonide - Strength: 0,5 mg/ml - Pharmaceutical form: 2 ml nebuliser suspension per respule The minimum requirements of the Article is described in more detail…

  10. LOT 10: Ciprofloxacin 2 mg/ml (100-200 ml per vial/ampoule, i.v., ATC J01MA02)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Ciprofloxacin 2 mg/ml (100-200 ml per vial/ampoule, i.v., ATC J01MA02) - Intravenous administration - Active pharmaceutical ingredient: Ciprofloxacin - Strength: 2 mg/ml - Pharmaceutical form: 100-200 ml per vial/ampoule The minimum requirements of the Article is described in more det…

  11. LOT 11: Streptomycin 1 g per vial/ampoule, i.m. (ATC J01GA01)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Streptomycin 1 g per vial/ampoule, i.m. (ATC J01GA01) - Powder for solution, intramuscular administration - Active pharmaceutical ingredient: Streptomycin - Strength: 1 g per vial/ampoule - Pharmaceutical form: vial/ampoule The minimum requirements of the Article is described in more…

  12. LOT 12: Meropenem 500-1000 mg per vial/ampoule, i.v. (ATC J01DH02)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Meropenem 500-1000 mg per vial/ampoule, i.v. ( ATC J01DH02) - Powder for solution, intravenous administration - Active pharmaceutical ingredient: Meropenem - Strength: 500-1000 mg per vial/ampoule - Pharmaceutical form: vial/ampoule The minimum requirements of the Article is described…

  13. LOT 13: Clindamycin 600 mg / 4 ml (4 ml per vial/ampoule, i.m. and i.v., ATC J01FF01)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Clindamycin 600 mg / 4 ml (4 ml per vial/ampoule, i.m. and i.v., ATC J01FF01) - Intramuscular administration and intravenous administration - Active pharmaceutical ingredient: Clindamycin - Strength: 600 mg / 4 ml - Pharmaceutical form: 4 ml per vial/ampoule The minimum requirements o…

  14. LOT 14: Ciprofloxacin 250-500 mg per tablet/capsule, oral (ATC J01MA02)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Ciprofloxacin 250-500 mg per tablet/capsule, oral (ATC J01MA02) - Oral solid dosage form - Active pharmaceutical ingredient: Ciprofloxacin - Strength: 250-500 mg per tablet/capsule - Pharmaceutical form: tablet/capsule The minimum requirements of the Article is described in more detai…

  15. LOT 15: Ethanol 95-96 % (5-20 ml per vial/ampoule, i.v., ATC V03AB16)

    The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Ethanol 95-96 % (5-20 ml per vial/ampoule, i.v., ATC V03AB16) - Intravenous administration - Active pharmaceutical ingredient: Ethanol - Strength: 95-96 % - Pharmaceutical form: 5-20 ml per vial/ampoule The minimum requirements of the Article is described in more detail in Annex 1.1.…

Sopimuskausi
1,1 v
Menettely
Avoin menettelyKaikki yritykset voivat jättää tarjouksen suoraan.
Suorituspaikka
Koko Suomi
Toimiala
Terveydenhuollon laitteet, lääkkeet ja hygieniatuotteetCPV-koodi 33600000, EU:n koodi hankinnan kohteelle
Osat
15, tarjous enintään 15 osaan
Sopimusmuoto
SopimusSopimus määrätystä toimituksesta.